A Phase 1a/1b Study Evaluating the Safety, Tolerability and Preliminary Efficacy of IBI322 Monotherapy or Combination Therapy in Subjects With Advanced Malignant Tumors.
Latest Information Update: 07 Sep 2023
At a glance
- Drugs IBI 322 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Innovent Biologics
- 04 Sep 2023 Status changed from active, no longer recruiting to completed.
- 10 Oct 2022 Status changed from not yet recruiting to active, no longer recruiting.
- 10 Oct 2022 Planned End Date changed from 20 Jun 2023 to 20 Sep 2023.